Business Context and Reporting Period
Company: Redhill Biopharma Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: November 2021 (Specifically November 9, 2021)
Context: This filing serves to incorporate by reference a press release announcing that Redhill Biopharma will present at the H.C. Wainwright 7th Annual Israel Conference and the German Equity Forum (EKF) 2021.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing to disclose an upcoming corporate event and does not contain financial statements or operational data.
Material Changes
No material financial changes versus the prior comparable period are reported in this filing. The document solely references the scheduling of investor presentations.
Guidance, Outlook, and Risks
Management Commentary: The company intends to present at two industry conferences in 2021 to discuss its business and pipeline.
Risks and Contingencies: No specific risks, contingencies, or unusual items are detailed in this filing text.
Guidance: No financial guidance or forward-looking projections are included in this specific report.
Investor Verification Checklist
- Verify the date and time of the presentations at the H.C. Wainwright Israel Conference and German Equity Forum (EKF) 2021.
- Review the full text of the press release attached as Exhibit 99.1 for any additional details on the presentation agenda.
- Check subsequent filings (e.g., Form 20-F or 8-K) for actual financial results and operational updates, as this 6-K contains none.